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athy and data on medical practice in case of gastropathy.
The time horizon was 3 months. Dyspepsia rates, ulcer
rates in patients with symptoms, and silent ulcer rates
were obtained from a large prospective trial (n  514)
and recalculated by using Bayesian analysis. Current
medical management of NSAID-related gastropathy was
obtained through a review of 102 patient records in pri-
mary care and through expert interviews (2 rounds Del-
phi method). Costs were taken from the perspective of
the health insurance. Unit costs were obtained from offi-
cial listings; hospitalization costs for peptic ulcer were
collected from a database of 58 hospitals. 
RESULTS: Effectiveness—expressed as number of pa-
tients free of symptomatic ulcer and as saved lives—was
greater for DM: 4 patients out of 100 developed symp-
tomatic ulcer, compared to 12 with D. In 100,000 pa-
tients, there would be 42 fatal cases with DM, compared
to 106 with D. At a daily cost of 45.57 BEF for DM and
33.46 for D, the results showed an average cost savings
of 2,834 BEF per patient if treated with DM, mainly be-
cause of a reduced hospitalization cost. Sensitivity analy-
sis around the confidence intervals of the key variables
did not change the conclusions. 
CONCLUSIONS: Diclofenac 
 misoprostol is a domi-
nating strategy compared to diclofenac alone. It prevents
gastropathy and is cost-saving for patients needing me-
dium- to long-term treatment with NSAIDs (3 months).
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ARTHRITIS STRATIFIED FOR SOCIAL STATUS
Merkesdal S, Ruof J, Mau W, Zeidler H
Department of Rheumatology, Medical School of Hannover, 
Hannover, Germany
OBJECTIVE: To assess the relationship between differ-
ent components of cost of illness and social status in an
early rheumatoid arthritis (RA) cohort.
METHODS: 133 consecutive outpatients (age: 47  10
years, 63% female) with early RA (mean disease duration:
7  4 months) fulfilling the diagnostic criteria for RA were
enrolled. All patients were gainfully employed at onset of
symptoms (T1). Data collection was performed using stan-
dardized interviews at T1 and 12 months later (T2). The
mean observation period was 19  4 months. Three major
cost components were analyzed: 1) costs for application
and monitoring of disease modifying antirheumatic drugs
(DMARD; direct costs), 2) loss of productivity due to sick
leave, work disability, and other work loss (indirect costs),
and 3) patient-related non-reimbursed costs. Social status
was measured by the patient education level (low or no de-
gree vs higher degrees).
RESULTS: The main results are shown in the table. Indi-
rect costs are significantly higher in patients with lower
levels of education and expenses concerning non-reim-
bursed treatment and medication tend to be less. No dif-
ferences can be seen in the use of DMARD.
CONCLUSION: Indirect costs were found to be especially
related to social strata in patients with early RA. Further
research is needed to identify indicators that may explain
these findings. Distinct therapeutic measures must be taken
for these patients already in early stages of the disease.
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OBJECTIVES: Quality of life (QoL) and related mea-
sures are increasingly used in the evaluation of patients
with arthritis. But a relatively uninvestigated area is the
relationship between QoL, healthcare resource utilization
and costs. We studied the ability of QoL measures to pre-
dict future healthcare resource use.
METHODS: 412 patients with osteoarthritis of the knee or
hip and 796 patients with rheumatoid arthritis completed
QoL assessments. Their healthcare resource use was mea-
sured 6 months later. QoL assessments included SF-36
physical and mental component scores (PCS, MCS), health
assessment questionnaire (HAQ), feeling thermometer (FT),
pain, fatigue (FAT), anxiety (ANX), satisfaction with health
(SAT), and comorbidity (COM). Healthcare resource use
included visits to all healthcare workers, GP/internal medi-
cine visits, hospitalizations, NSAID usage, and gastrointesti-
nal (GI) drug use.
RESULTS: In general, after controlling for the effect of
demographic variables, the best predictors for physician
visits were QoL mental components, global health mea-
sures, and patient global assessment of health. Comorbid-
ity was the best predictor for hospitalization. Use of
Major cost components dichotomized by education level
Education level DMARDcosts
Indirect
costs
Patient-related
costs
Low degree (n  72) 115 552 DM 40 095 DM 690 DM
High degree (n  61) 90 627 DM 22 935 DM 1252 DM
Student’s t-test p  0.1 p  0.005 p  0.1
PCS MCS HAQ FT ANX FAT GIS Pain SAT COM Global
HCV 4.70 7.28 7.12 4.83 5.40 6.35 3.28 5.38 8.75 4.78 6.58
GIV 5.59 7.36 5.61 6.44 5.16 6.12 5.50 5.98 7.39 6.89 6.82
HOSP 1.14 3.85 1.42 2.24 3.09 3.45 2.69 2.07 2.54 4.39 4.81
NSAID 2.59 0.29 2.63 2.34 0.60 2.06 1.78 1.67 2.07 0.24 1.10
GI 1.51 4.69 1.99 4.45 4.23 3.97 8.96 3.63 2.09 6.87 3.12
Z-scores: 1.96  p  0.05; 2.58  p: 0.01; 3.28  p  0.01.
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NSAIDs was not influenced by any QoL variables. Co-
morbidity, severity of GI symptoms (GIS), and the MCS
all had a significant impact on GI medication use. In mul-
tivariate analyses, MCS, HAQ, satisfaction with health
and comorbidity were independent predictors of health-
care resource use. Results have clinical relevance, as, for
example, a 1-unit change in HAQ predicts one additional
visit per 6 months. 
CONCLUSIONS: QoL measures and health rating scales
both can be used to predict healthcare resource use. Men-
tal health is important in predicting healthcare resource
use among patients with arthritis.
PHARMACOECONOMIC METHODS AND COST 
OF CARE
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OBJECTIVE: The objective was to investigate the com-
pliance and expenditure impact of pharmacist’s cognitive
services (i.e., services that require clinical skills, such as
patient education).
METHODS: Data came from the Cognitive Activities and
Reimbursement Effectiveness Project (CARE), and from
Washington State Medicaid. There were three groups of
pharmacies: a group that was paid to provide cognitive
services (n  110), a group that was not paid but did doc-
ument the provision of cognitive service (n  90), and a
control group (n  100) matched to patients in the paid
and nonpaid groups. Data were collected for 6 months of
both baseline and follow-up. There were 992 patients from
the paid group pharmacies, 554 from the nonpaid, and
6,021 from the control group. The outcomes of interest
were 1) medication noncompliance, 2) utilization of ser-
vices, and 3) expenditures. The analysis focused on seven
target diseases (epilepsy, depression, heart disease, throm-
bolic disease, hypertension, diabetes, and schizophrenia).
RESULTS: The paid and nonpaid groups were 31% less
likely to be noncompliant (OR  0.69; 95% CI 0.51–
0.94) than the control group. The likelihood of compli-
ance increased with increasing numbers of services per
patient. Total cost was not significantly increased (p 
0.05) for the paid or nonpaid group. There was an in-
crease in prescription cost and use for target diseases in
the paid and nonpaid group (p  0.05), but there was
also a contemporaneous trend (p  0.05) toward de-
creased cost of other components of care.
CONCLUSION: Paying for cognitive services may be cost
neutral overall, while increasing the likelihood of favorable
clinical outcomes through gains in medication compliance.
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OBJECTIVE: To determine the baseline running cost of
maintaining a patient in a general medical ward for 1 day.
METHOD: Forty-three patients (19 males, 24 females)
were retrospectively randomly selected from January
through July 1997 from medical admission lists of the fol-
lowing specialties: cardiology, neurology, rheumatology,
endocrinology, gastroenterology, infectious diseases, and
hematology. Data on patients’ demographics, medications,
clinical and laboratory investigations and procedures were
collected from patients’ files. Fixed and variable costs were
identified and costed. Fixed costs included nursing, biomed-
ical engineering, laundry, catering, cleaning, maintenance,
and administration overheads, but excluded the costs of the
hospital building per se. Among the variable costs were
professional fees, including those of physicians, clinical
pharmacists, physiotherapists, and dieticians. The average
daily running cost was calculated and comparative analysis
was made for differences between sex and age groups.
RESULTS: The average daily running cost (in US dollars)
of maintaining a patient in a general medical ward was
$202. There was no statistical difference (p  0.05) for
either sex ($196: $203, male: female) or age group ($193:
$204, (30: 30).
CONCLUSION: This study determined the daily baseline
running cost of maintaining a patient in a general medical
ward. Both fixed and variable costs were comparable for
sex and age groups, but the fixed costs were almost dou-
ble the variable costs. This was a helpful pilot study and
provided a base for further future larger studies in deter-
mining the average daily running costs of maintaining pa-
tients in general medical wards.
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OBJECTIVE: In the comparison between an innovative
treatment versus a standard reference treatment, modern
cost-effectiveness studies evaluate the survival data of the
two treatments and determine the survival gain, using a
long-term time horizon. These studies are often con-
ducted in the area of biotechnology drugs (e.g., the new-
